Mostrando 10 resultados de: 13
Filtros aplicados
Área temáticas
Enfermedades(7)
Farmacología y terapéutica(6)
Bioquímica(4)
Fisiología humana(4)
Eudicotas y Ceratofilales(1)
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer
ArticleAbstract: Targeted cancer therapies, although often effective, have limited utility owing to preexisting primaPalabras claves:Autores:Bader A.G., Chen X., Dysart S., Esteban A. Orellana, Kasinski A.L., Kelnar K., Shimer E., Slack F.J., Stahlhut C., Zhao J.Fuentes:scopusFolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer
ArticleAbstract: MicroRNAs are small RNAs that negatively regulate gene expression posttranscriptionally. Because chaPalabras claves:Autores:Esteban A. Orellana, Kasinski A.L., Low P.S., Lyle L.T., Rangasamy L., Tenneti S.Fuentes:scopusIn tobacco BY-2 cells xyloglucan oligosaccharides alter the expression of genes involved in cell wall metabolism, signalling, stress responses, cell division and transcriptional control
ArticleAbstract: Xyloglucan oligosaccharides (XGOs) are breakdown products of XGs, the most abundant hemicelluloses oPalabras claves:BY-2 cells, cell cycle, Cell walls, Microarray analysis, NICOTIANA TABACUM, Xyloglucan oligosaccharidesAutores:Acosta A., Albani D., Bitonti B.M., Bruno L., Cabrera J.C., Esteban A. Orellana, Francis D., Lien González-Pérez, Perrotta L., Rogers H.J., Spadafora N.Fuentes:googlescopusEnhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin
ArticleAbstract: The therapeutic promise of small-RNA therapeutics is limited, not only by the lack of delivery vehicPalabras claves:DELIVERY, endosomal escape, folate, folate-conjugates, ligand, microRNA, miR-34, nigericinAutores:Abdelaal A.M., Esteban A. Orellana, Kasinski A.L., Low P.S., Myoung S., Rangasamy L., Tenneti S.Fuentes:scopusIdentification and validation of microRNAs that synergize with miR-34a–a basis for combinatorial microRNA therapeutics
ArticleAbstract: Efforts to search for better treatment options for cancer have been a priority, and due to these effPalabras claves:combinatorial therapeutics, miR-34, miR-34a, miRNA therapeutics, Mirna-34, synergismAutores:Esteban A. Orellana, Kasinski A.L., Li C., Lisevick A.Fuentes:scopusMETTL1-mediated m<sup>7</sup>G modification of Arg-TCT tRNA drives oncogenic transformation
ArticleAbstract: The emerging “epitranscriptomics” field is providing insights into the biological and pathological rPalabras claves:Arg-TCT, Cáncer, m G 7, METTL1, N -methylguanosine 7, oncogene, translation, tRNAAutores:Ali R., Aspris D., Bernardes G.J.L., Bradley A., De Braekeleer E., Esteban A. Orellana, Fischer E.S., Garyfallos D.A., Gregory R.I., Gu M., Gutierrez A., Lim J., Liu Q., Mikutis S., Pirouz M., Sendinc E., Slack F.J., Tzelepis K., Vassiliou G.S., Yankova E., Zhang W.Fuentes:scopusMETTL4 is an snRNA m<sup>6</sup>Am methyltransferase that regulates RNA splicing
OtherAbstract:Palabras claves:Autores:Chen H., Esteban A. Orellana, Gregory R.I., Gu L., Guo J., Liu Q., Shen Z., Shi Y., Wang L., Wang Y., Wu H., Xing Y.Fuentes:scopusMicrornas in cancer: A historical perspective on the path from discovery to therapy
ReviewAbstract: Recent progress in microRNA (miRNA) therapeutics has been strongly dependent on multiple seminal disPalabras claves:Cáncer, History, microRNA, therapeuticsAutores:Esteban A. Orellana, Kasinski A.L.Fuentes:scopusNew Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K<sup>+</sup>/H<sup>+</sup> Exchange
ArticleAbstract: Although peptides, antibodies/antibody fragments, siRNAs, antisense DNAs, enzymes, and aptamers arePalabras claves:Autores:Bandara N.A., Chelvam V., Esteban A. Orellana, Kanduluru A.K., Kasinski A.L., Low P.S., Rangasamy L., Srinivasarao M., You F.Fuentes:scopusNo vehicle, no problem
OtherAbstract:Palabras claves:MiRNA, siRNAAutores:Esteban A. Orellana, Kasinski A.L.Fuentes:scopus